News

Forest gains Cerexa’s antibiotic portfolio from the deal, which includes Cerexa’s lead compound ceftaroline acetate. The drug, which is in phase III trials, exhibits bactericidal activity against the

Intellect has said the antibodies are difficult to generate and so the acquisition could significantly accelerate its product development timeline. The antibodies are intended as a form of

The completion of this milestone allows Ecopia to initiate the second portion of its clinical trial, the extension phase. During the dose-escalation portion of this trial, ECO-4601 was

AbGenomics Corporation intends to use the PER.C6 cell line for its research, development and early clinical studies of monoclonal antibodies. “The unique characteristics of the PER.C6 technology as

The transaction is expected to close within the next two weeks. At closing, $7.5 million in cash and $4.375 million in LAB shares will be paid. The sellers

The trial is designed to monitor the safety and tolerability of PBI-1402 and whether it has additive effects when combined with the current drug for anemia, erythropoietin (EPO)

The construction has been halted because the company expects to be able to meet the growth in insulin demand with already existing manufacturing sites and new insulin capacity

The close follows the early termination by the US Federal Trade Commission of the waiting period under the Hart-Scott-Rodino Antitrust Act. Pradefovir is an experimental hepatitis B drug,

Entelos is providing biosimulation services to J&J, compensated in part through the grant of this option, and will develop a new PhysioLab platform to support its internal development